Клинический Институт Мозга
|
Клинический Институт Мозга |
||
| |||
Список литературы2. Рекомендации Европейского комитета по инсульту (перевод с английского European Stroke Initiative, Recommendations 2003 (E U S I) «Ischemic Stroke (prophylaxis and treatment)» Волковой Л.И., г.Екатеринбург, 2004, 69 с. 3. Антонов И.П., Лупьян Я.А. Справочник по диагностике и прогнозированию нервных болезней в таблицах и перечнях. Минск, 1986, С.92-100. 4. Белова А.Н. Нейрореабилитация: руководство для врачей – 2-е изд., перераб. и доп. – М.: Антидор, 2002 . 5. Методические рекомендации по организации неврологической помощи больным с инсультами в Санкт-Петербурге. – С-Петерб: Человек, 2002. 6. Шкалы, тесты и опросники в медицинской реабилитации: под ред. А.Н.Беловой, О.Н. Щепетовой. – М.: Антидор, 2002. 7. Верещагин Н.В., Зуслина З.А., Пирадов М.А. Принципы диагностики и лечения больных с острыми ишемическими нарушениями мозгового кровообращения. Атмосфера. Нервные болезни.-2002. №1. С.8-14. 8. Верещагин Н.В. Гетерогеннность инсульта в клинической практике. Ж. Атмосфера. Нервные болезни. -2004. -№1. С.19-20. 9. Гусева Л.Л. Лечебная гимнастика и массаж у больных с постинсультными двигательными нарушениями. Методическое письмо.-М. 1970. 12 с. 10. Стаховская Л.В. с соавт. Вторичная профилактика инсульта. Консилиум медикум. Специальный выпуск. 2003. С. 35-38. 11. Гусев Е.И., В.И.Скворцова с соавт. Эпидемиология инсульта в России. Консилиум медикум. Специальный выпуск. 2003. С. 5-7. 12. Гусев Е.И., В.И.Скворцова. Терапия ишемического инсульта. Консилиум медикум. Специальный выпуск. 2003. С.18-25. 13. Инсульт. Принципы диагностики, лечения и профилактики/ Под ред. Н.В.Верещагина, М.А.Пирадова, З.А.Суслиной. – М.: Интермедика, 2002.- 208 с. 14. Суслина З.А. Ишемический инсульт: принципы лечения в острейшем периоде. –Атмосфера. Нервные болезни. -№1. -2004. С.14-18. 15. Шмидт Е.В. Классификация сосудистых поражений головного и спинного мозга. Журнал невропатологии и психиатрии им. С.С.Корсакова. -1985. -выпуск 9. –с.1282-1291. 16. Fisher A. Emerging therapies for cerebrovascular disorders. Strike. 2004;35(2):367-369. 17. Warburton E. Stroke management. Clin.Evidence 2003;10:231-245. 18. Reed S.D. Inpatients costs, length of stay, and mortality for cerebrovascular events in community hospitals: Neurology. 2001;57:305-314. 19. Wattigney WA, Croft JB, Mensah GA, et al. Establishing data elements for the Paul Coverdell National Acute Stroke Registry: Part 1: proceedings of an expert panel. Stroke. 2003;34:151-156. Abstract 20. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151-1158. Abstract 21. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke. 2003;34:1056-1083. Abstract 22. Khaw KT. Epidemiology of stroke. J Neurol Neurosurg Psychiatry. 1996;61:333-338. Abstract 23. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Available at http://www.americanheart.org/ presenter.jhtml?identifier=3009972. Accessed June 17, 2003. 24. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke. 2002;33:1209-1213. Abstract 25. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;30:2523-2528. Abstract 26. Sturm JW, Dewey HM, Donnan GA, MacDonell RA, McNeil JJ, Thrift AG. Handicap after stroke: How does it relate to disability, perception of recovery, and stroke subtype? the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2002;33:762-768. Abstract 27. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med. 2000;343:710-722. Abstract 28. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry. 2002;52:253-264. Abstract 29. Teasell R, McRae M, Foley N, Bhardwaj A. The incidence and consequences of falls in stroke patients during inpatient rehabilitation: factors associated with high risk. Arch Phys Med Rehabil. 2002;83:329-333. Abstract 30. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515-522. Abstract 31. Brittain K. Stroke and continence care. Nurs Times. 2001;97:57. 32. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222. Abstract 33. NINDS Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587. Abstract 34. Caplan LR. Stroke treatment: promising but still struggling. JAMA. 1998;279:1304-1306. Abstract 35. Ronning OM, Guldvog B. Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial. Stroke. 1998;29:58-62. Abstract 36. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment. 10-year follow-up. Stroke. 1999;30:1524-1527. Abstract 37. Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988-1997. Stroke. 2001;32:2221-2226. Abstract 38. Brown MM. Brain attack: a new approach to stroke. Clin Med. 2002;2:60-65. Abstract 39. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996;94:1167-1174. Abstract 40. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150. Abstract 41. Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA. 1998;279:1293-1297. Abstract 42. Fontanarosa PB, Winker MA. Timely and appropriate treatment of acute stroke: what's missing from this picture? JAMA. 1998;279:1307-1309. 43. Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998;279:1288-1292. Abstract 44. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743. Abstract 45. Tuhrim S. Management of hemorrhagic stroke. Curr Cardiol Rep. 2002;4:158-163. Abstract 46. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the risk of hemorrhagic stroke in men. Stroke. 2003;34:1151-1155. Abstract 47. Wolfe CD, Rudd AG, Howard R, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72:211-216. Abstract 48. Casper M, Wing S, Strogatz D. Variation in the magnitude of black-white differences in stroke mortality by community occupational structure. J Epidemiol Community Health. 1991;45:302-306. Abstract 49. Kapral MK, Wang H, Mamdani M, Tu JV. Effect of socioeconomic status on treatment and mortality after stroke. Stroke. 2002;33:268-273. Abstract 50. Boden-Albala B, Sacco RL. Socioeconomic status and stroke mortality: refining the relationship. Stroke. 2002;33:274-275. Abstract 51. Schneider AT, Pancioli AM, Khoury JC, et al. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA. 2003;289:343-346. Abstract 52. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke. 1997;28:1530-1540. Abstract 53. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026. Abstract 54. Connors JJ, III. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. Rev Cardiovasc Med. 2002;3(Suppl 2):S92-S99. 55. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med. 2002;30:S332-S340. Abstract 56. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787. Abstract 57. Christou I, Felberg RA, Demchuk AM, et al. Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroimaging. 2002;12:119-123. Abstract 58. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251. Abstract 59. J.P.Broderic. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke;1999;30;905-915 60. N.Pouratian. Update on Management of Intracerebral Hemorrhage. Neurosurg Focus 15(4), 2003. |
||||
|
[ О НАС ] [ ПАЦИЕНТАМ ] [ СПЕЦИАЛИСТАМ ] [ СОТРУДНИЧЕСТВО ] [ ССЫЛКИ ]
|
||||
